logo
French intelligence: China used embassies to undermine sales of France's flagship Rafale fighter jet

French intelligence: China used embassies to undermine sales of France's flagship Rafale fighter jet

Yahoo21 hours ago
PARIS (AP) — China deployed its embassies to spread doubts about the performance of French-made Rafale jets after they saw combat in India and Pakistan's clashes in May, French military and intelligence officials have concluded, implicating Beijing in an effort to hammer the reputation and sales of France's flagship fighter.
Findings from a French intelligence service seen by The Associated Press say defense attaches in China's foreign embassies led a charge to undermine Rafale sales, seeking to persuade countries that have already ordered the French-made fighter — notably Indonesia — not to buy more and to encourage other potential buyers to choose Chinese-made planes. The findings were shared with AP by a French military official on condition that the official and the intelligence service not be named.
Four days of India-Pakistan clashes in May were the most serious confrontation in years between the two nuclear-armed neighbors, and included air combat that involved dozens of aircraft from both sides. Military officials and researchers have since been digging for details of how Pakistan's Chinese-made military hardware — particularly warplanes and air-combat missiles — fared against weaponry that India used in airstrikes on Pakistani targets, notably French-made Rafale fighters.
Sales of Rafales and other armaments are big business for France's defense industry and help efforts by the government in Paris to strengthen ties with other nations, including in Asia where China is becoming the dominant regional power.
France is fighting what it calls a disinformation campaign against the Rafale
Pakistan claimed its air force downed five Indian planes during the fighting, including three Rafales. French officials say that prompted questions about their performance from countries that have bought the fighter from French manufacturer Dassault Aviation.
India acknowledged aircraft losses but didn't say how many. French air force chief Gen. Jérôme Bellanger said that he's seen evidence pointing to just 3 Indian losses — a Rafale, a Russian-made Sukhoi and a Mirage 2000, which is an earlier generation French-made jet. It was the first known combat loss of a Rafale, which France has sold to eight countries.
'Of course, all those, the nations that bought Rafales, asked themselves questions,' Bellanger said.
French officials have been battling to protect the plane from reputational damage, pushing back against what they allege was a concerted campaign of Rafale-bashing and disinformation online from Pakistan and its ally China.
They say the campaign included viral posts on social media, manipulated imagery showing supposed Rafale debris, AI-generated content and video-game depictions to simulate supposed combat. More than 1,000 social media accounts newly created as the India-Pakistan clashes erupted also spread a narrative of Chinese technological superiority, according to French researchers who specialize in online disinformation.
French military officials say they haven't been able to link the online Rafale-bashing directly to the Chinese government.
Intelligence assessment says Chinese officials lobbied potential clients to ditch French planes
But the French intelligence service said Chinese embassy defense attaches echoed the same narrative in meetings they held with security and defense officials from other countries, arguing that Indian Air Force Rafales performed poorly and promoting Chinese-made weaponry.
The defense attaches focused their lobbying on countries that have ordered Rafales and other potential customer-nations that are considering purchases, the intelligence service said. It said French officials learned of the meetings from nations that were approached.
Asked by AP to comment on the alleged effort to dent the Rafale's appeal, the Ministry of National Defense in Beijing said: 'The relevant claims are pure groundless rumors and slander. China has consistently maintained a prudent and responsible approach to military exports, playing a constructive role in regional and global peace and stability.'
In recent years, China has stepped up disinformation campaigns on global social media platforms like X, Instagram or Facebook, using networks of state-sponsored influencers, sites that pose as news organizations, and fake social media accounts to spread narratives from Beijing.
France's Defense Ministry said the Rafale was targeted by 'a vast campaign of disinformation" that 'sought to promote the superiority of alternative equipment, notably of Chinese design.'
France considers the jet a 'strategic French offering'
"The Rafale was not randomly targeted. It is a highly capable fighter jet, exported abroad and deployed in a high-visibility theater," the Defense Ministry wrote on its website.
'The Rafale was also targeted because it represents a strategic French offering. By attacking the aircraft, certain actors sought to undermine the credibility of France and its defense industrial and technological base. The disinformation campaign therefore did not merely target an aircraft, but more broadly a national image of strategic autonomy, industrial reliability, and solid partnerships.'
Dassault Aviation has sold 533 Rafales, including 323 for export to Egypt, India, Qatar, Greece, Croatia, the United Arab Emirates, Serbia and Indonesia. Indonesia has ordered 42 planes and is considering buying more.
China may be hoping to weaken the security relationships that France is building with Asian nations by spreading worries about the equipment it supplies, said Justin Bronk, an airpower specialist at the Royal United Services Institute, a defense and security think tank in London.
'From a point of view of limiting Western countries' influence in the Indo-Pacific, it would make sense for China to be using the performance of Pakistani weapon systems — or at least purported performance — in downing at least one Rafale as a tool to undermine its attractiveness as an export,' he said.
'They certainly saw an opportunity to damage French sales prospects in the region."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Celebrating the Future of Accounting - One Student at a Time
Celebrating the Future of Accounting - One Student at a Time

Yahoo

time6 minutes ago

  • Yahoo

Celebrating the Future of Accounting - One Student at a Time

London School of Business & Finance Singapore Campus Recognised as ISCA Registered Learning Organisation SINGAPORE, July 7, 2025 /PRNewswire/ -- At the ISCA SCAQ Top Achievers & Partners Recognition Ceremony held on 13 May 2025, LSBF Singapore was recognised as an ISCA Registered Learning Organisation. The event brought together leading voices in the profession to celebrate the outstanding achievements of students in the Singapore Chartered Accountant Qualification (SCAQ) programme — and to honour the education partners shaping their journey. This recognition is more than a badge of honour — it's a reflection of LSBF's belief in the power of education, mentorship, and hands-on experience to transform aspiring accountants into confident, future-ready professionals. "We're deeply invested in the growth of our learners," said Yvonne Goh, Head of School of Professional Education, LSBF Singapore. "Whether in the classroom or through real-world exposure, our goal is to equip them not just with technical skills, but with the mindset to lead in a fast-changing world." Mr David Yeong, Head of ISCA Academy, said, "At ISCA, we believe that shaping the next generation of Chartered Accountants requires strong partnerships with Registered Learning Organisations (RLOs) who share our commitment of innovation and excellence. LSBF Singapore exemplifies this spirit through innovative teaching and dedicated support for students pursuing the SCAQ. We look forward to working together to nurture future Chartered Accountants and advancement of the accountancy profession." LSBF's SCAQ tutors, who joined the celebration, continue to play a vital role in delivering rigorous, relevant, and inspiring learning experiences. Together, LSBF is proud to support a new generation of Chartered Accountants who will drive progress in the industry. About London School of Business & Finance (LSBF) The London School of Business & Finance (LSBF), founded in 2003 and a member of the Global University System (GUS), serves over 25,000 students across more than 40 countries. With campuses in key cities including the UK, Singapore, and Malaysia, LSBF has expanded its international footprint, particularly in Asia. LSBF Singapore campus offers over 100 programmes in business, finance, law, hospitality, and technology, and collaborate with reputable universities to provide internationally recognised qualifications. LSBF holds EduTrust certification, partners with organizations like Grab, Deloitte and ISCA, and is an ACCA Approved Learning Partner. In recognition of its future-focused approach to education, LSBF was honoured with the Singapore Business Review's International Business Award in Education for two consecutive years – 2024 and 2025. These accolades reaffirm LSBF's commitment to delivering quality, industry-aligned education that empowers aspiring professionals globally. View original content to download multimedia: SOURCE London School of Business & Finance Singapore Campus Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

France's Macron to visit UK as Starmer eyes 'reset' with EU
France's Macron to visit UK as Starmer eyes 'reset' with EU

Yahoo

time6 minutes ago

  • Yahoo

France's Macron to visit UK as Starmer eyes 'reset' with EU

French President Emmanuel Macron is to begin a state visit to the United Kingdom on Tuesday, where he is set to address the British Parliament and co-chair a meeting on Ukraine as London seeks to strengthen its ties with Europe after Brexit. King Charles III has invited the French leader and his wife, Brigitte, on a three-day official visit during which Macron is to hold joint discussions with Prime Minister Keir Starmer at the 37th Franco-British Summit on Thursday. Talks will focus on aid to Ukraine, joint efforts to halt illegal migration crossing the Channel, and strengthening defence cooperation between the two countries. "This is the first state visit to the United Kingdom by a European Union head of state since Brexit," the Elysee Palace said on Friday, referring to the UK's 2016 vote to leave the bloc. "And, especially, the first since Prime Minister Starmer signalled what he called a 'reset' of relations between the United Kingdom and Europe,", it added. There were simmering political tensions between Paris and London in the immediate aftermath of Brexit under the previous right-wing Conservative British government. But there has been a new warmth in relations under the centre-left Labour government led by Starmer, and the two countries now lead European efforts to find peace for Ukraine. Buckingham Palace confirmed on Friday that Macron would formally address the British Parliament on Tuesday, following in the footsteps of his predecessors, Charles de Gaulle and Francois Mitterrand. The king will host Macron and his wife for a state banquet at his Windsor Castle residence, west of London, where the couple will also stay. While in Windsor, Macron will privately visit St George's Chapel to lay flowers on the tomb of the late Queen Elizabeth II. -'Reassurance force'- During the visit, Macron and Starmer will host the 37th Franco-British Summit in London on Thursday, where they are set to discuss opportunities to strengthen defence ties between the two countries in response to Russia's full-scale invasion of Ukraine. The agreements will be "adapted to this profoundly changed strategic reality", the Elysee Palace said, without offering further details. Macron and Starmer will also co-chair talks bringing together countries "willing" to strengthen Kyiv's defences against Moscow. The two leaders will speak with Ukrainian President Volodymyr Zelensky, as well as German Chancellor Friedrich Merz and Italian Prime Minister Giorgia Meloni, the French presidency said. This comes after the United States, Ukraine's biggest military backer since the launch of Russia's full-scale invasion in 2022, said Tuesday it was halting some key weapons shipments to Ukraine. Russia launched its largest-ever drone and missile attack on Ukraine overnight on Friday. The summit will touch upon the deployment of "a reassurance force" to Ukraine after a ceasefire and how to "increase pressure" on Russia to accept an unconditional ceasefire, the Elysee Palace said. Another topic high on the agenda is agreeing on a strategy to halt migrants making perilous small boat crossings of the Channel, a key political issue in the UK. As more small boats land on English shores, and the UK government comes under mounting pressure from the far right to tackle irregular migration, London has pressed Paris to do more. In recent weeks, France said it is considering stopping migrant boats in its shallow coastal waters, though the move raises safety and legal issues. And on Friday, the British government said it welcomed footage showing French police stopping a small boat carrying migrants from setting off across the Channel. The French president's visit follows King Charles's state visit to France in 2023, which was widely regarded as a success that helped boost relations. The last state visit by a French president to the UK was made by Nicolas Sarkozy in 2008. vl/ekf/yad

Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

Yahoo

time7 minutes ago

  • Yahoo

Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li BEIJING, July 07, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that on June 30, the United States District Court for the District of Massachusetts denied Vivo Capital's petition against 1Globe Capital LLC ("1Globe") for relief relating to SINOVAC's shareholder votes and corporate governance. In its ruling, the Court concluded, "relief relating to governance outcomes or shareholder votes – are DENIED without prejudice." The Massachusetts ruling marks the fourth unsuccessful legal attempt by either Advantech/Prime Success ("Advantech/Prime") or Vivo Capital (together "the Dissenting Investor Group") to strip SINOVAC common shareholders of their rightful dividend payments. This result follows Advantech/Prime's recently failed petition in New York and Advantech/Prime and Vivo Capital's recently failed petition in Hong Kong – which were repeated attempts to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the Company's payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. The Dissenting Investor Group continues to interfere with the current Board's fiduciary duties to implement the UK Privy Council's unappealable ruling in January 2025. In this ruling, the UK Privy Council deemed the former illegitimate board an "Imposter Board" and handed 1Globe – the investment arm of a cancer-focused global R&D group and SINOVAC's largest shareholder – a victory on all grounds. In addition, the UK Privy Council Judicial Committee, comprising five UK Supreme Court Justices, concluded that there was "nothing unlawful in the conduct of 1Globe" in connection with SINOVAC's 2018 AGM. The Dissenting Investor Group's self-serving, multi-pronged lawfare strategy is crystal clear: (1) block actions taken by the SINOVAC Board to distribute rightful dividend payments to valid SINOVAC common shareholders; (2) protect the ill-gotten gains it stripped from SINOVAC subsidiaries over the past seven years; and (3) regain control of SINOVAC in order to continue to loot the Company. Having failed in the courtroom, the Dissenting Investor Group has decided to instead use deceptive and false stories to attack 1Globe and its founder Dr. Chiang Li, who chairs the current SINOVAC Board. As noted in SINOVAC's proxy materials, Dr. Li is an accomplished clinician, scientist, inventor, entrepreneur and a seasoned executive with international recognitions. Dr. Li and 1Globe have successfully challenged the Dissenting Investor Group's abuse in court for the past seven years and championed the rights and interests of all valid SINOVAC shareholders. During those seven years, The Dissenting Investor Group, in coordination with the former illegitimate board (the "Imposter Former Board"), pursued the following schemes: Privatization attempt at a below-market price in 2016, which would have succeeded had it not been for the efforts of 1Globe (who declined an invite by the Former Management Buyout Group to join and profit from its privatization attempt); Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; Commitment by the Imposter Former Board to invest ~US$139 million of SINOVAC cash into a venture fund managed by Vivo Capital – creating a clear conflict of interest. This would be in addition to the approximately US$100 million SINOVAC has already invested into Vivo Capital funds. US$15 million debt investment into Sinovac Life Sciences Co., Ltd. ("SLS"), a wholly owned subsidiary of SINOVAC, in exchange for a 15% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$1 billion of distributions made to the Dissenting Investor Group. In contrast, SINOVAC common shareholders have received no dividends and haven't been able to trade their shares for the past six years. To add insult to injury, the Imposter Former Board publicly stated in April 2024 in the Company's 2023 20-F that it had "no plan to pay any cash dividends on SINOVAC Antigua's shares in the foreseeable future"; Barrage of baseless and wasteful legal action in 2025, after refusing to accept the Privy Council's non-appealable ruling, with the goal of interfering with the dividend payment unless the Dissenting Investor Group is able to double dip on dividends already received from SLS; Deceptive and disparaging campaign against current SINOVAC board members that is meant to intimidate them and interfere with the stability and function of the current Board. The Dissenting Investor Group's hostile actions, baseless claims and wasteful litigation are evidence that it poses a direct threat to the value of your investment and the future of SINOVAC. Don't let the Dissenting Investor Group, which is working in coordination with SAIF and is represented on SAIF's Reconstituted Imposter Former Board, regain control of the Company. If the Reconstituted Imposter Former Board succeeds, it will put all valid shareholders' future dividend payments at risk – this includes the current Board's announced plans for an additional US$11.00 per common share cash dividend, contingent on the cancellation of the unauthorized PIPE shares, and its adopted policy to issue regular dividends out of surplus cash. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card "AGAINST" Proposal 1 to remove the current Board and "AGAINST" Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store